CHRS logo

CHRS
Coherus Biosciences Inc

5,098
Mkt Cap
$271.42M
Volume
906,351.00
52W High
$2.62
52W Low
$0.71
PE Ratio
-1.20
CHRS Fundamentals
Price
$1.75
Prev Close
$1.76
Open
$1.76
50D MA
$1.72
Beta
1.84
Avg. Volume
1.48M
EPS (Annual)
-$1.45
P/B
3.48
Rev/Employee
$286,884.35
$48.58
Loading...
Loading...
News
all
press releases
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·9d ago
News Placeholder
More News
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Coherus Oncology (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat·9d ago
News Placeholder
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages
Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...
MarketBeat·18d ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average - Should You Sell?
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...
MarketBeat·23d ago
News Placeholder
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat·1mo ago
News Placeholder
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.
Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an innovative oncology company focused...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen
Wall Street Zen raised Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Coherus Oncology Q4 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an innovative oncology company during its fourth-quarter and full-year 2025 earnings call, highlighting a growing commercial base...
MarketBeat·2mo ago
<
1
2
...
>

Latest CHRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.